title: [Potential indications for helical tomotherapy in breast cancers].
abstract: OBJECTIVE
  To evaluate the dosimetric gain obtained in either the planning target volume or organs at risk coverage by the use of intensity-modulated radiation therapy in some particular postoperative breast cancers.
  
  
  METHODS
  Prospective dosimetric comparison between monoisocentric conformal radiotherapy and intensity-modulated radiation therapy in nine patient files.
  
  
  RESULTS
  Using intensity-modulated radiation therapy was shown to improve in each case, at least one conformity, homogeneity, and coverage index either for planning target volumes or for organs at risk. Intensity-modulated radiation therapy was therefore always chosen rather than conformal monoisocentric radiotherapy.
  
  
  CONCLUSIONS
  Indications to retain intensity-modulated radiation therapy would consist of bilateral lesions, pectus excavatum, past thoracic irradiation (Hodgkin's disease) and complex volumes in obese or overweight patients.
authors: Département de radiothérapie, institut Jean-Godinot, rue du Général-Koenig, 51100 Reims, France.
authors: F
authors: F
authors: Lamberth
authors: Département de radiothérapie, institut Jean-Godinot, rue du Général-Koenig, 51100 Reims, France.
authors: P
authors: P
authors: Guilbert
authors: Unité de radiophysique médicale, institut Jean-Godinot, rue du Général-Koenig, 51100 Reims, France.
authors: N
authors: N
authors: Gaillot-Petit
authors: Unité de radiophysique médicale, institut Jean-Godinot, rue du Général-Koenig, 51100 Reims, France.
authors: C
authors: C
authors: Champagne
authors: Unité de radiophysique médicale, institut Jean-Godinot, rue du Général-Koenig, 51100 Reims, France.
authors: L
authors: L
authors: Looten-Vieren
authors: Département de radiothérapie, institut Jean-Godinot, rue du Général-Koenig, 51100 Reims, France. Electronic address: Tandat.nguyen@reims.unicancer.fr.
authors: T D
authors: TD
authors: Nguyen
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000532:radiotherapy*; D018275:Carcinoma, Lobular / Q000188:drug therapy / Q000532:radiotherapy; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005660:Funnel Chest / Q000150:complications; D006689:Hodgkin Disease / Q000532:radiotherapy; D006801:Humans; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000532:radiotherapy; D016609:Neoplasms, Second Primary / Q000532:radiotherapy; D009765:Obesity / Q000150:complications; D011880:Radiotherapy Planning, Computer-Assisted; D020266:Radiotherapy, Conformal / Q000379:methods; D050397:Radiotherapy, Intensity-Modulated; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil
keywords: Breast cancer; Cancer du sein; Intensity modulation; Modulation d’intensité; Radiotherapy; Radiothérapie